| Literature DB >> 32874057 |
In Woong Han1, Kyeongwon Cho2, Youngju Ryu1, Sang Hyun Shin1, Jin Seok Heo1, Dong Wook Choi1, Myung Jin Chung2, Oh Chul Kwon3, Baek Hwan Cho4.
Abstract
BACKGROUND: Despite advancements in operative technique and improvements in postoperative managements, postoperative pancreatic fistula (POPF) is a life-threatening complication following pancreatoduodenectomy (PD). There are some reports to predict POPF preoperatively or intraoperatively, but the accuracy of those is questionable. Artificial intelligence (AI) technology is being actively used in the medical field, but few studies have reported applying it to outcomes after PD. AIM: To develop a risk prediction platform for POPF using an AI model.Entities:
Keywords: Neural networks; Pancreatoduodenectomy; Postoperative pancreatic fistula; Recursive feature elimination
Mesh:
Year: 2020 PMID: 32874057 PMCID: PMC7438201 DOI: 10.3748/wjg.v26.i30.4453
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Clinicopathologic variables included in the machine learning algorithms
| Age (yr) | 67.7 ± 10.1 | Preoperative ERBD/ENBD ( | 470 (26.6) |
| Sex (male/female) | 1079: 690 | Preoperative PTBD ( | 254 (14.4) |
| Body mass index (kg/m2) | 22.5 ± 3.8 | Preoperative ERPD ( | 19 (1.1) |
| Heart disease including hypertension ( | 735 (41.5) | Neoadjuvant therapy (RT/chemotherapy/CCRT/No) | 2: 6: 16: 1745 |
| Diabetes mellitus ( | 472 (26.7) | Operative time (min) | 443.2 ± 90.1 |
| Pulmonary disease ( | 153 (8.6) | †Intraoperative fluid infusion (mL) | 3129 ± 3495 |
| Liver disease ( | 99 (5.6) | Intraoperative transfusion ( | 171 (9.7) |
| Cerebrovascular disease ( | 73 (4.1) | Estimated blood loss (ml) | 962.4 ± 665.1 |
| Chronic kidney disease ( | 17 (1.0) | Soft pancreas ( | 750 (43.2) |
| ASA score (1-4) | 372:1267: 128: 2 | Pancreatic duct diameter (mm) | 4.2 ± 2.8 |
| White blood cell count (x10³/μL) | 6.6 ± 2.3 | Type of surgery (PPPD/PRPD/PD) | 1254: 244: 271 |
| Hemoglobin (g/dL) | 10.9 ± 1.5 | Combined organ resection ( | 67 (3.8) |
| Platelet count (x10³/μL) | 280.2 ± 52.7 | Combined vascular resection( | 188 (10.6) |
| Albumin (d/dL) | 3.5 ± 0.4 | C- reactive protein (mg/dL) | 1.9 ± 10.9 |
| Total bilirubin level (mg/dL) | 3.5 ± 4.3 | CA 19-9 (U/mL) | 1786.5 ± 7141.5 |
| Combined portal vein resection ( | 175 (9.9) | P-duct stent (Internal/external/none) | 1051: 134: 584 |
| Amylase (U/L) | 94.5 ± 5586.9 | Co-existing pancreatitis ( | 370 (20.9) |
| Lipase (U/L) | 160.5 ± 277.0 | ‡Location of tumor (Pancreas/others) | 856: 913 |
| Anastomotic methods (1) (Duct-to-mucosa/Dunkin) | 1756: 13 | Anastomotic methods (2) (P-J/P-G/Others) | 1761: 8: 0 |
Total fluid infusion consisted of total amount of intravenous crystalloid, colloid, transfusion. 377 ampulla of Vater cancers, 446 bile duct cancers, 90 duodenal cancers. Pancreatic cystic tumors and neuroendocrine tumors belonged to pancreas. RBD: Endoscopic retrograde biliary drainage; ENBD: Endoscopic nasogastric biliary drainage; PTBD: Percutaneous transhepatic biliary drainage; ERPD: Endoscopic retrograde pancreatic drainage; RT: Radiotherapy; CCRT: Concomitant chemo- and radiotherapy; PP- or PRPD: Pylorus-preserving or pylorus-resecting pancreaticoduodenectomy; CA: Carbohydrate antigen; P-J: Pancreaticojejunostomy; P-G: Pancreaticogastrostomy.
Prediction performance of the various dataset for postoperative pancreatic fistula
| Random forest with complete cases | 38 | 44 | 889 | 0.670.02 |
| Neural network with complete cases | 0.740.02 | |||
| Random forest with complete variables | 34 | 40 | 1769 | 0.670.01 |
| Neural network with complete variables | 0.720.02 | |||
| Random forest with missing data treatment | 38 | 44 | 1769 | 0.680.02 |
| Neural network with missing data treatment | 0.710.02 |
Figure 1Performance of the neural network models optimized within each recursive feature elimination step. 1: Pancreatic duct diameter; 2: Body mass index; 3: Serum albumin; 4: Amount of intraoperative fluid infusion; 5: Age; 6: Platelet count; 7: Extrapancreatic location of tumor; 8: Combined venous resection; 9: Co-existing pancreatitis; 10: Serum lipase; 11: Neoadjuvant radiotherapy; 12: ASA score; 13: Sex; 14: Soft texture of pancreas; 15: Underlying heart disease; 16: Preoperative endoscopic biliary decompression; 17: Hemoglobin; 18: Serum total bilirubin; 19: Operative time; 20: Intraoperative transfusion; 21: Neoadjuvant chemotherapy; 22: Anastomotic methods (1); 23: Serum amylase; 24: Anastomotic methods (2-1); 25: Pancreatic duct stent (1); 26: White blood cell count; 27: Type of surgery (1); 28: Serum carbohydrate antigen 19-9; 29: Serum C- reactive protein; 30 Estimated blood loss; 31: Combined vascular resection; 32: Pancreatic duct stent (2); 33: Preoperative percutaneous biliary drainage; 34: Underlying cerebrovascular disease; 35: Combined organ resection; 36: Type of surgery (2); 37: Type of surgery (3); 38: Anastomotic methods (2-2); 39: Underlying liver disease; 40: Underlying chronic kidney disease; 41: Underlying pulmonary disease; 42: Underlying cerebrovascular disease; 43: Diabetes mellitus; 44: Preoperative endoscopic pancreatic drainage; ASA: American Society of Anesthesiologists; AUC: Area under the curve.
Figure 2Illustration of artificial intelligence algorithm for 16 risk factors affecting postoperative pancreatic fistula. PV-SMV: Portal vein-superior mesenteric vein; ASA: American Society of Anesthesiologists; ERBD: Endoscopic retrograde biliary drainage; ENBD: Endoscopic nasobiliary drainage; POPF: Postoperative pancreatic fistula.